Compare Bank of Nova Scotia (BNS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Sana Biotechnology Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $108.32B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Bank of Nova Scotia is far larger — about 95.9× Sana Biotechnology Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BNS | SANA | |
|---|---|---|
Market Cap | $108.32B | $1.13B |
Sector | Financials | Health |
52-Week High | $90.29 | $5.92 |
52-Week Low | $56.41 | $2.68 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $90.34, up 2.01% with a bullish technical outlook supported by moving averages. The bank has delivered three consecutive earnings beats, with Q2 2026 EPS expected at $1.53. Recent acquisition of MapleMark Bank and dividend increase to $1.14 demonstrate strategic growth initiatives. Valuation metrics show P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a compelling investment case with strong fundamentals and analyst support (52.63% buy ratings), though revenue growth has been modest and interest expenses remain elevated. The stock faces risks from economic uncertainty and credit quality concerns, but dividend stability and improving ROE to 11.87% provide downside protection. Upside potential exists if the bank maintains earnings momentum.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
